Previous 10 | Next 10 |
home / stock / dskyf / dskyf news
AstraZeneca (AZN) and Daiichi Sankyo ([[DSKYF]] +2.5%) have reported updated results from Phase 2 trial of Enhertu, which continued to demonstrate ‘impressive’ efficacy and durable responses in patients with HER2-positive metastatic breast cancer.Updated data demonstrated t...
Daiichi Sankyo Co Ltd (DSKYF) Q2 2021 Earnings Conference Call November 02, 2020, 02:30 ET Company Participants Junichi Onuma - VP, Corporate Communications Department Sunao Manabe - President & Group CEO Wataru Takasaki - Executive Officer & Head, R&D Division Toshiaki Sai - CFO ...
The following slide deck was published by Daiichi Sankyo Company, Limited in conjunction with their 2020 Q2 earnings call. For further details see: Daiichi Sankyo Company, Limited 2020 Q2 - Results - Earnings Call Presentation
Daiichi Sankyo Co. (DSKYF): 1H GAAP EPS of ¥26.53.Revenue of ¥480.17B (+0.1% Y/Y)Press Release For further details see: Daiichi Sankyo Co. reports 1H results
AstraZeneca (AZN) and collaboration partner Daiichi Sankyo (DSKYF) announce the FDA acceptance of a supplemental marketing application seeking approval to use Enhertu (trastuzumab deruxtecan) to treat HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.The agency's ac...
The following slide deck was published by Daiichi Sankyo Company, Limited in conjunction with this event. For further details see: Daiichi Sankyo (DSNKY) Presents At ESMO Follow-Up Meeting Hosted By Citi - Slideshow
Daiichi Sankyo ( OTCPK:DSKYF ) has out-licensed global rights to cancer candidate DS-3032 (milademetan) to privately held Rain Therapeutics who will develop the orally available small molecule MDM2 inhibitor as RAIN-32. More news on: Daiichi Sankyo Company, Limited, Daiichi Sankyo Co...
Publication highlights Europe -specific one-year follow-up findings for atrial fibrillation (AF) patients in routine clinical practice, in which, rates of stroke, systemic embolism, and major bleeding are considered by the authors to be low in edoxaban treated patients [1] Findings...
Daiichi Sankyo ( OTCPK:DSKYF ) will collaborate with AstraZeneca (NYSE: AZN ) on a clinical trial evaluating the combination of patritumab deruxtecan (U3-1402), an HER3-directed DXd antibody-drug conjugate, and the latter's Tagrisso (osimertinib), an epidermal growth factor receptor (E...
RedHill Biopharma (NASDAQ: RDHL ) has replaced its existing 2015 co-commercialization agreement with Daiichi Sankyo ( OTCPK:DSKYF ) for Movantik (naloxegol) with a new royalty-bearing agreement, under April 2020 acquisition agreement with AstraZeneca (NYSE: AZN ) . More news on: Red...
News, Short Squeeze, Breakout and More Instantly...
Daiichi Sankyo Co Ltd Company Name:
DSKYF Stock Symbol:
OTCMKTS Market:
Publication highlights Europe -specific one-year follow-up findings for atrial fibrillation (AF) patients in routine clinical practice, in which, rates of stroke, systemic embolism, and major bleeding are considered by the authors to be low in edoxaban treated patients [1] Findings...
· Results published in the European Heart Journal – Cardiovascular Pharmacotherapy , showed rates of thromboembolism similar to those observed in the ENGAGE AF-TIMI 48 clinical trial [1] · Study reports LIXIANA outcomes from one of the largest observational ...
- ENTRUST-AF PCI study achieved the primary safety endpoint of non-inferiority in bleeding for edoxaban-based dual therapy compared with VKA-based triple antithrombotic therapy (using a risk-based duration of ASA for at least one month) in AF patients following stent placement - ...